53,383 Shares in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Bought by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC bought a new position in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 53,383 shares of the company’s stock, valued at approximately $114,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Intech Investment Management LLC boosted its position in shares of Black Diamond Therapeutics by 49.1% during the 4th quarter. Intech Investment Management LLC now owns 19,247 shares of the company’s stock worth $41,000 after acquiring an additional 6,340 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Black Diamond Therapeutics by 429.6% during the 4th quarter. JPMorgan Chase & Co. now owns 18,929 shares of the company’s stock worth $41,000 after acquiring an additional 15,355 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Black Diamond Therapeutics during the 4th quarter worth about $42,000. Wells Fargo & Company MN boosted its position in shares of Black Diamond Therapeutics by 41.8% during the 4th quarter. Wells Fargo & Company MN now owns 20,119 shares of the company’s stock worth $43,000 after acquiring an additional 5,932 shares in the last quarter. Finally, Sei Investments Co. acquired a new position in shares of Black Diamond Therapeutics during the 4th quarter worth about $49,000. 95.47% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently issued reports on BDTX shares. Wedbush reaffirmed an “outperform” rating and set a $11.00 price objective on shares of Black Diamond Therapeutics in a research report on Wednesday, March 19th. Stifel Nicolaus reduced their target price on Black Diamond Therapeutics from $16.00 to $15.00 and set a “buy” rating for the company in a report on Friday, March 7th. Finally, HC Wainwright boosted their target price on Black Diamond Therapeutics from $11.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, March 18th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $14.60.

Black Diamond Therapeutics Trading Up 1.0%

Shares of BDTX opened at $1.95 on Monday. The firm has a market capitalization of $110.88 million, a P/E ratio of -1.47 and a beta of 2.63. The stock’s fifty day simple moving average is $1.60 and its 200 day simple moving average is $2.11. Black Diamond Therapeutics, Inc. has a twelve month low of $1.20 and a twelve month high of $6.75.

Black Diamond Therapeutics (NASDAQ:BDTX) last announced its earnings results on Thursday, March 6th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.03. Sell-side analysts predict that Black Diamond Therapeutics, Inc. will post -1.3 earnings per share for the current year.

Insider Buying and Selling at Black Diamond Therapeutics

In other news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of Black Diamond Therapeutics stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $2.07, for a total transaction of $11,973,484.44. Following the sale, the insider now owns 2,733,547 shares of the company’s stock, valued at approximately $5,658,442.29. The trade was a 67.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 8.87% of the stock is currently owned by insiders.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.